Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The company's CEO, Taylor Schreiber, M.D., Ph.D., will deliver a presentation on April 9, 2025, at 3:00 PM EDT and participate in one-on-one meetings during the conference, which runs from April 7-10, 2025. A live webcast of the presentation will be accessible through the company's website, with a replay available for up to 30 days afterward.
Shattuck Labs (NASDAQ: STTK), un'azienda biotecnologica focalizzata nello sviluppo di nuove terapie mirate ai recettori della superfamiglia TNF per malattie infiammatorie e immunologiche, ha annunciato la sua partecipazione alla prossima 24ª Conferenza Virtuale Annuale di Needham sulla Sanità.
Il CEO dell'azienda, Taylor Schreiber, M.D., Ph.D., presenterà il 9 aprile 2025, alle 15:00 EDT e parteciperà a incontri individuali durante la conferenza, che si svolgerà dal 7 al 10 aprile 2025. Una trasmissione in diretta della presentazione sarà accessibile attraverso il sito web dell'azienda, con una registrazione disponibile per un massimo di 30 giorni successivi.
Shattuck Labs (NASDAQ: STTK), una empresa biotecnológica centrada en el desarrollo de nuevas terapias dirigidas a los receptores de la superfamilia TNF para enfermedades inflamatorias y relacionadas con el sistema inmunológico, ha anunciado su participación en la próxima 24ª Conferencia Virtual Anual de Salud de Needham.
El CEO de la empresa, Taylor Schreiber, M.D., Ph.D., realizará una presentación el 9 de abril de 2025, a las 3:00 PM EDT y participará en reuniones individuales durante la conferencia, que se llevará a cabo del 7 al 10 de abril de 2025. Una transmisión en vivo de la presentación estará disponible a través del sitio web de la empresa, con una repetición accesible durante hasta 30 días después.
샤택랩스 (NASDAQ: STTK), TNF 초가족 수용체를 겨냥한 새로운 치료제를 개발하는 데 중점을 둔 생명공학 회사가 다가오는 제24회 니드햄 가상 의료 회의에 참여할 것이라고 발표했습니다.
회사의 CEO인 테일러 슈라이버, M.D., Ph.D.는 2025년 4월 9일 오후 3시 EDT에 발표를 진행하고, 2025년 4월 7일부터 10일까지 열리는 회의 동안 일대일 회의에 참여할 예정입니다. 발표의 실시간 웹캐스트는 회사 웹사이트를 통해 접근 가능하며, 이후 30일 동안 재생할 수 있습니다.
Shattuck Labs (NASDAQ: STTK), une entreprise de biotechnologie axée sur le développement de nouvelles thérapies ciblant les récepteurs de la superfamille TNF pour les maladies inflammatoires et liées au système immunitaire, a annoncé sa participation à la prochaine 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
Le PDG de l'entreprise, Taylor Schreiber, M.D., Ph.D., fera une présentation le 9 avril 2025 à 15h00 EDT et participera à des réunions individuelles pendant la conférence, qui se déroulera du 7 au 10 avril 2025. Une diffusion en direct de la présentation sera accessible via le site web de l'entreprise, avec un replay disponible pendant jusqu'à 30 jours après.
Shattuck Labs (NASDAQ: STTK), ein biotechnologisches Unternehmen, das sich auf die Entwicklung neuartiger Therapeutika zur gezielten Behandlung von TNF-Superfamilienrezeptoren für entzündliche und immunologische Erkrankungen konzentriert, hat seine Teilnahme an der bevorstehenden 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt.
Der CEO des Unternehmens, Taylor Schreiber, M.D., Ph.D., wird am 9. April 2025 um 15:00 Uhr EDT eine Präsentation halten und an Einzelgesprächen während der Konferenz teilnehmen, die vom 7. bis 10. April 2025 stattfindet. Ein Live-Stream der Präsentation wird über die Unternehmenswebsite zugänglich sein, mit einer Wiederholung, die bis zu 30 Tage später verfügbar ist.
- None.
- None.
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.
Conference Details
Format: Presentation and one-on-one meetings
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: April 9, 2025
Time: 3:00 PM EDT
Webcast link: HERE
A live webcast of the 24th Annual Needham Virtual Healthcare Conference presentation will be available on the Events and Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.
About SL-325
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 has completed a GLP toxicology study in non-human primates, with an IND filing expected in the third quarter of 2025.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
When is Shattuck Labs (STTK) presenting at the 2025 Needham Healthcare Conference?
How long will STTK's Needham Conference presentation replay be available?
What therapeutic areas does Shattuck Labs (STTK) focus on?
Who will represent Shattuck Labs (STTK) at the 2025 Needham Healthcare Conference?
